An Open-Label, Dose Escalation, Phase I Study of MLN4924, a Novel Inhibitor of Nedd8-Activating Enzyme, in Adult Patients With Nonhematologic Malignancies
Inclusion Criteria:
- Male or female patients 18 years or older
- Eastern Cooperative Oncology Group performance status 0-2
- Patients must have a diagnosis of a nonhematologic malignancy for which standard
curative, life-prolonging, or palliative treatment does not exist or is no longer
effective.
- Expected survival longer than 6 weeks from enrollment in the study
- Radiographically or clinically evaluable tumor
- Suitable venous access for the conduct of blood sampling for MLN4924
- Tumor tissue that, in the opinion of the investigator, can be safely biopsied using a
core needle
- Male patients must use an appropriate method of barrier contraception
- Female patients must be postmenopausal, surgically sterilized, or willing to use
reliable methods of birth control
- Voluntary written consent
Exclusion Criteria:
- Pregnant or lactating
- Major surgery within 14 days prior to the first dose of study treatment
- Serious infection within 14 days prior to the first dose of study treatment
- Receiving antibiotic therapy within 14 days prior to the first dose of study
treatment
- Life-threatening illness unrelated to cancer
- Diarrhea that is greater than Grade 1 in severity
- Systemic antineoplastic therapy within 21 days preceding first dose of study
treatment
- Radiotherapy within 21 days preceding first dose of study treatment
- Prior treatment with radiation therapy involving ≥25% of the hematopoietically active
bone marrow
- CYP3A inducers within 14 days before the first dose of MLN4924. Moderate and strong
CYP3A inhibitors and CYP3A inducers are not permitted during the study.
- Clinically significant central nervous system metastases
- Absolute neutrophil count <1,500/mm3; platelet count <100,000/mm3
- Patients with a prothrombin time or aPTT > 1.5 x the upper limit of the normal range,
or with a history of a coagulopathy or bleeding disorder
- Ongoing anti-coagulant therapy that can not be held to permit tumor biopsy
- Calculated creatinine clearance <50 mL/minute
- Bilirubin >1.5 times the upper limit of normal; aspartate aminotransferase, alanine
aminotransferase, or alkaline phosphatase >2.5 times the upper limit of normal.
- Uncontrolled cardiovascular conditions, including cardiac arrhythmias, congestive
heart failure, angina, or myocardial infarction within the past 6 months
- Abnormalities on 12-lead electrocardiogram including, but not limited to, changes in
rhythm and intervals that in the opinion of the investigator are considered to be
clinically significant
- Known human immunodeficiency virus positive or hepatitis B surface antigen-positive
status, or known or suspected active hepatitis C infection
- Treatment with any investigational products within 28 days preceding the first dose
of study treatment